Tariq I Mughal and John M Goldman malignancy is well characterised, molecular targeting
may be a remarkably effective therapy.• Complete eradication of residual disease may …

The success of the tyrosine kinase imatinib inhibitor (Gleevec, STI571) in treating chronic
myeloid leukemia as well as other selected cancers has greatly increased optimism for the …

Inhibition of oncogenic protein kinases by small compound inhibitors has proven to be a
valuable strategy for the directed and target-specific treatment of an ever-increasing number …

When the tyrosine kinase inhibitor imatinib (Gleevec) was found to induce high remission
rates in patients with chronic myeloid leukemia, this was hailed as a success for targeted …

A British humorist said,“There is much to be said for failure. It is much more interesting than
success.” This CCR Focus section is aimed at identifying lessons to be learned from …

More than a decade ago, imatinib, an agent that has a specific inhibitory interaction with the
BCR-ABL fusion protein, was introduced for the treatment of chronic myeloid leukemia …

The 5-year IRIS (International Randomized study of Interferon vs STI571) data, confirming
the excellent results with imatinib for chronic myeloid leukaemia (CML), were a highlight at …

Tyrosine kinases (TKs) are involved in different cellular functions including extracellular
signalling, intracellular communication, proliferation, cell cycle control or apoptosis/survival …

Cancer is a heterogeneous disease with diverse underlying molecular causes and equally
diverse clinical profiles. It has long been a goal to develop cancer therapies that would be …

Over the past few years, a number of anticancer drugs have been developed that specifically
target kinases known to be oncogenic. The leading drug in this area is imatinib mesylate …